ImmuCell Corp. (NASDAQ:ICCC) Q4 2018 Earnings Conference Call - Final Transcript

Feb 14, 2019 • 09:00 am ET


ImmuCell Corp. (NASDAQ:ICCC) Q4 2018 Earnings Conference Call - Final Transcript


Loading Event

Loading Transcript


Good morning, and welcome to the ImmuCell Corporation reports Fourth Quarter and Full Year 2018 Financial Results Conference Call. All participants will be in a listen-only mode. (Operator Instructions) After today's presentation there will be an opportunity to ask questions. (Operator Instructions) Please note that this event is being recorded.

I would now like to turn the conference over to Joe Diaz with Lytham Partners. Please go ahead.

Joe Diaz

Thank you, Chad. Good morning and welcome to the ImmuCell fourth quarter 2018 earnings conference call. Thanks to all of you for joining us today. As a reminder, today's call is being recorded. My name is Joe Diaz with Lytham Partners. We're the Investor Relations consulting firm for ImmuCell. Please note that the unaudited summary press release that was filed with the Securities and Exchange Commission last night is available to you and that the full audited details of the Company's 2018 financial results will be available toward the end of March, when the Company files its annual report on Form 10-K with the SEC.

I would like to preface this discussion today with a caution regarding forward-looking statements. Listeners are reminded that statements made by management during the course of this call include forward-looking statements that are subject to risks and uncertainties, that could cause actual results to differ materially from those discussed today. Additional information regarding these risks and uncertainties available under the cautionary note regarding forward-looking statements in the Company's press release that was issued last night as well as on the Company's periodic filings with the SEC, which can be obtained from the SEC or by visiting the Investors section of the Company's website at

With that said, let me turn to Michael Brigham, President and CEO of ImmuCell Corporation, after which we will open the call for your questions. Michael?

Michael Brigham

Great. Thank you, all for taking the time to join today's call. I do appreciate that. Let me start by saying Happy Valentine's Day to all. Also I have to apologize, I'm just coming out of quite a cold. So forgive me for the scratchy voice here. I'm going to go a bit off script today and just speak to the top of mind about a few things that I think are important to note about the press release, disclosures we made last night. As Joe mentioned, more complete and audited review of 2018 will be available when we file our Annual Report on Form 10-K towards the end of March.

So top line, to start with sales, you can see sales are up 5%. This is in a very difficult dairy economy, I mean we really do see and feel the pain of our customers. So we're quite pleased to be up with a 5% increase. And Tri-Shield is driving a lot of that increase and I'll talk about that as my second topic. The fourth quarter was off a bit, I see Seeking Alpha picks that up as a title, as a headliner. And if